Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän

The effect of LongoVital … - Göteborgs universitet Till startsida
Till innehåll Läs mer om hur kakor används på gu.se



OBS! Vill du ha svar, ange e-post eller telefonnummer!

The effect of LongoVital on recurrent aphthous stomatitis in a controlled clinical trial.

Artikel i vetenskaplig tidskrift
Författare John Bratel
Magnus Hakeberg
Mats Jontell
Publicerad i Oral health & preventive dentistry
Volym 3
Nummer/häfte 1
Sidor 3-8
ISSN 1602-1622
Publiceringsår 2005
Publicerad vid Odontologiska institutionen
Sidor 3-8
Språk en
Länkar www.ncbi.nlm.nih.gov/entrez/query.f...
Ämnesord Adult, Aged, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Phytotherapy, Plant Components, Plant Preparations, therapeutic use, Plants, Medicinal, Recurrence, prevention & control, Statistics, Nonparametric, Stomatitis, Aphthous, prevention & control, Tablets, Vitamins, therapeutic use
Ämneskategorier Odontologi, Övrig odontologi


PURPOSE: The aim of this study was to evaluate the effect of daily intake of LongoVital (LV) (herbal vitamin tablets) in the prevention of RAS. MATERIALS AND METHODS: A group of 78 consecutively referred patients was enrolled to a three-months pretreatment period. Fifty subjects were then randomly allocated to an LV-group (n = 25) or a placebo group (N = 25). A double blind, stratified-randomised clinical case-control study was performed during six months. Number and size of the ulcers were registered by the patients using a standardized chart. The degree of discomfort was recorded on a 100 mm horizontal visual analogue scale (VAS-scale). RESULTS: The three-months pretreatment period revealed that the most dominant symptoms were pain (78%) followed by burning sensation (18%). No significant differences between the two groups were found during this period when a comparison was made at the end of the study. After the intervention period the number of aphthous ulcers/month decreased significantly in the LV-group (p = 0.02). The number of days in pain/month were also reduced (p < 0.001). If a 50% reduction of number of aphthous ulcers and days in pain were considered as clinically relevant, no statistical significant differences were found between the groups. CONCLUSION: Thus, no strong evidence was found that justified a recommendation of LV as a general drug for treatment of RAS.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?